UBS reiterates Buy on Aritzia stock, sees revenue doubling by 2032
UBS has maintained its Buy rating on Aritzia Inc., forecasting a potential twofold increase in revenue by fiscal year 2032. The price target set by UBS stands at Cdn$228.00, with the company's stock presently valued at a market cap of $12.3 billion. UBS attributes Aritzia's promising growth prospects to their investments in store concepts, brand relevance, product diversification, and digital capabilities. The firm's confidence in the company's long-term runway was bolstered following Aritzia's recent Investor Day.
UBS anticipates Aritzia's revenue to expand to a range of C$9.5 billion to C$10.5 billion by the end of 2032, alongside an increase in adjusted EBITDA margin by approximately 100 basis points to 21%. The PEG ratio of 0.28 suggests that the growth potential relative to valuation is attractive. Despite the stock's overvaluation according to Fair Value metrics, UBS remains optimistic about Aritzia's sales growth and margin levers. The firm projects a 27% compound annual growth rate in earnings per share over the next five years.
Aritzia's robust financial performance, as demonstrated in its second-quarter earnings report, has further strengthened UBS's bullish outlook on the company. Net revenue surged by 44% year-over-year, reaching CAD 1.17 billion, while the adjusted EBITDA margin reached a record high of 21%. Following these impressive results, Aritzia raised its full-year fiscal 2027 outlook, reflecting gains across both its physical stores and online sales.
These developments highlight Aritzia's solid performance and strategic outlook, despite a slight recent decline in the stock price. Investors are now evaluating the impressive results against future growth expectations. The company's revenue growth can be attributed to strong demand in both the U.S. and Canadian markets. This article was compiled with the assistance of AI and reviewed by an editor, for more details, please refer to the provided Terms and Conditions.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.